Usage Examples
- We booked a PMDA consultation on the Phase 3 design before locking the protocol.
- The PMDA review is the science; the approval still has to come through MHLW, so budget for both.
- We need a Marketing Authorization Holder in Japan in place before the PMDA filing, not after.
What is PMDA (Pharmaceuticals and Medical Devices Agency)?
PMDA is Japan's incorporated administrative agency that scientifically reviews drugs, medical devices, and cellular and tissue-based products for marketing approval, inspects the data and plants behind them, and runs post-marketing safety and relief services alongside MHLW.
PMDA exists because Japan separated the science from the authority. Established on 1 April 2004 as an incorporated administrative agency, PMDA consolidated product review, post-marketing safety, and relief for adverse health effects into a single body that sees a product across its whole life. Its stated obligation is to protect public health by assuring the safety, efficacy and quality of pharmaceuticals and medical devices.
PMDA covers drugs, medical devices, and cellular and tissue-based products, evaluating their quality, efficacy and safety in light of current scientific and technological standards, and inspecting both the submitted data and the manufacturing facility behind it. PMDA does not hold the approval itself: it reviews from the scientific aspect and works together with the Ministry of Health, Labour and Welfare, which owns pharmaceutical policy and the approval decision.
PMDA runs on pre-submission engagement. Various types of consultation services are provided by the agency, and the advice from those meetings shapes what the review will later accept, so sponsors book them long before filing. PMDA also expects the application to sit behind a Marketing Authorization Holder located in Japan, which makes the local entity a gating item rather than paperwork.
Not to be confused with
- MHLW
- MHLW is the ministry that sets pharmaceutical policy and carries the approval decision. PMDA is the agency that performs the scientific review and works together with it. Naming PMDA as the approving authority understates the ministry-level step.
- FDA
- FDA reviews and approves inside one agency. Japan splits those roles, so a completed PMDA review is not an approval and a Japanese timeline contains a step that US-built plans routinely omit.
- ICH
- ICH writes harmonised guidelines; PMDA is the Japanese regulator that applies them. Conforming to an ICH guideline does not by itself answer a PMDA review question.
- A Japanese sales affiliate
- a commercial affiliate is not automatically the Marketing Authorization Holder. PMDA states these procedures should be implemented by Marketing Authorization Holders located in Japan, which is a specific regulatory role.
There is no single PMDA checklist. These are the obligations that shape a Japanese filing.
What you must do
- 1Submit the application for PMDA evaluation of quality, efficacy, and safety of the drug, device, or cellular and tissue-based product against current scientific and technological standardsPMDA Reviews and Related Services - evaluation scope
- 2Prepare for two inspection tracks alongside the dossier review: GLP/GCP/GPSP inspections of the submitted data, and GMP/QMS/GCTP inspections of the manufacturing facilityPMDA Reviews and Related Services - inspections
- 3Appoint a Marketing Authorization Holder located in Japan to implement the application and post-marketing procedures before the dossier movesPMDA FAQ - Marketing Authorization Holder located in Japan
- 4Plan the approval as a two-body process, with PMDA performing the review and working together with the Ministry of Health, Labour and WelfarePMDA Outline - relationship with MHLW
- 5Hold the dossier to a public-health standard, not a filing standard: PMDA's stated obligation is assuring the safety, efficacy and quality of the productPMDA Outline - mission
Common mistakes
Naming PMDA as the approving authority
PMDA reviews from the scientific aspect and works together with MHLW, which holds pharmaceutical policy and the approval decision. Strategy decks that collapse the two compress the Japanese timeline and set a launch date the ministry step cannot support.
Leaving the Japanese Marketing Authorization Holder until filing
PMDA states the procedures should be implemented by Marketing Authorization Holders located in Japan. Discovering that after the dossier is written costs months of entity setup, contracting, and pharmacovigilance transfer before anything can be submitted.
Assuming a US or EU dossier ports to Japan
PMDA runs its own GLP/GCP/GPSP data inspections and GMP/QMS/GCTP facility inspections. A package built for FDA review is not automatically inspection-ready in Japan, and each inspection track carries its own lead time and remediation risk.
When This Matters
- We booked a PMDA consultation on the Phase 3 design before locking the protocol.
- The PMDA review is the science; the approval still has to come through MHLW, so budget for both.
- We need a Marketing Authorization Holder in Japan in place before the PMDA filing, not after.
Frequently Asked Questions
PMDA does the science; MHLW carries the authority. PMDA is the agency that reviews the quality, safety and efficacy of medical products to be marketed in Japan from a scientific aspect, and it works together with the Ministry of Health, Labour and Welfare, which sets pharmaceutical policy and owns the approval decision.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
